Abstract: The present disclosure provides the synthesis of an imidazolium-based functional ionic liquid copolymer (PMMA-b-PIL-R*) and a preparation method of an alloy ultra-filtration membrane. Firstly, PMMA-b-PIL-R* is prepared from methyl methacrylate (MMA) and polymerizable imidazolium-based functional ionic liquid (IL-R*) containing double bonding as the reactive monomers through sequential radical polymerization. With the use of a non-solvent induced phase separation method, PMMA-b-PIL-R* is introduced into the body of a polymeric membrane material, so as to prepare an alloy ultra-filtration membrane. A hydrogen-bond interaction is generated between the carbonyl in the molecular chain of PMMA-b-PIL-R* and the H . . .

Abstract: The present disclosure provides the synthesis of an imidazolium-based functional ionic liquid copolymer (PMMA-b-PIL-R*) and a preparation method of an alloy ultra-filtration membrane. Firstly, PMMA-b-PIL-R* is prepared from methyl methacrylate (MMA) and polymerizable imidazolium-based functional ionic liquid (IL-R*) containing double bonding as the reactive monomers through sequential radical polymerization. With the use of a non-solvent induced phase separation method, PMMA-b-PIL-R* is introduced into the body of a polymeric membrane material, so as to prepare an alloy ultra-filtration membrane. A hydrogen-bond interaction is generated between the carbonyl in the molecular chain of PMMA-b-PIL-R* and the H . . .

Abstract: Use of triacontanol in preparation of human medicaments for treatment of cancers, especially liver cancer, intestinal cancer, and lung cancer. Triacontanol can be formulated into many formulations, such as oral tablets, capsules, drop pills, sustained-released formulation, injectable solution, injectable powder, suspension, and emulsion.

Abstract: A method for producing dihydrocucurbitacin F-25-0-acetate consisting of the steps as followed: percolating radix hemsleyae using acetone as solvents to obtain extract; eluting the extract in silica gel column using chloroform: methanol as eluting agent (gradient) to obtain the crude; recrystallizating the crude using methanol or ethanol to obtain di-hydrocucurbitacin F-25-O-acetate (purity:>98%). And the use of dihydrocucurbitacin F-25-O-acetate in the manufacture of medicaments for treating cancers of liver, lung, stomach, larynx, prostate and leukemia.

Abstract: Use of triacontanol in preparation of human medicaments for treatment of cancers, especially liver cancer, intestinal cancer, and lung cancer. Triacontanol can be formulated into many formulations, such as oral tablets, capsules, drop pills, sustained-released formulation, injectable solution, injectable powder, suspension, and emulsion.